TheEdgeResearch
Home / Stocks / STLN

Starling Oncology, Inc. (STLN)

NASDAQ Healthcare Medical - Care Facilities
$3.00 ▼ -5.66%
Market Cap
$306.0M
Sector
Healthcare
Industry
Medical - Care Facilities
Beta
0.42
52-Wk Range
2.32-7.13
CEO
Daniel Virnich
Country
US
Currency
USD

Starling Oncology, Inc. operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Cerritos, CA, US. The stock last traded at $3.00, down 5.66% on the session, giving a market capitalisation of $306.0M. On trailing twelve-month figures it carries a trailing P/E of -10.34, a net margin of -5.7%. Its beta of 0.42 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-10.34
Price / Sales
0.49
Price / Book
-8.27
EV / EBITDA
-38.07
Gross margin
16.5%
Operating margin
-3.3%
Net margin
-5.7%
Return on equity
—
Debt / equity
-2.62
Current ratio
1.11
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
641
IPO date
2026-08-04
Headquarters
Cerritos, CA, US
About Starling Oncology, Inc.

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

More research on STLN
STLN technical analysis STLN TheEdge Score Compare against peers
Open full interactive analysis & DCF →